WuXi PharmaTech, an open-access R&D capability and technology platform company serving the pharma, biotech and medical device industries with operations in China and the U.S., has announced an enhancement to its genomics services. The WuXi Genome Center will provide Chinese researchers who use its gene sequencing services with access to the integrated sequence analysis capabilities of NextCODE Health, a bioinformatics company based in Cambridge, Mass.
NextCODE offers the world's only genome analysis system developed at population scale, with uniquely fast and proven capabilities for diagnosing rare diseases and gauging risk of common conditions. NextCODE will work with the WuXi Genome Center to process gene sequencing data of WuXi's customers and produce a report discussing the data's medical implications. This enhancement further enables the research community to leverage the power of next generation sequencing and data analysis for better diagnosis and treatment of disease.